Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-epigallocatechin 3-gallate | multiple interactions | ISO | SNX25 (Homo sapiens) | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX25 mRNA | CTD | PMID:22079256 | 1,2-dichloroethane | decreases expression | ISO | Snx25 (Mus musculus) | 6480464 | ethylene dichloride results in decreased expression of SNX25 mRNA | CTD | PMID:28960355 | 1,2-dimethylhydrazine | decreases expression | ISO | Snx25 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of SNX25 mRNA | CTD | PMID:22206623 | 1,2-dimethylhydrazine | multiple interactions | ISO | Snx25 (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of SNX25 mRNA | CTD | PMID:22206623 | 17beta-hydroxy-5alpha-androstan-3-one | increases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Dihydrotestosterone results in increased expression of SNX25 mRNA | CTD | PMID:29581250 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SNX25 mRNA | CTD | PMID:21215274 and PMID:33387578 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Snx25 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of SNX25 mRNA | CTD | PMID:21570461 | 2,3,7,8-Tetrachlorodibenzofuran | increases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:32109520 | 2,4-dinitrotoluene | affects expression | EXP | | 6480464 | 2 and 4-dinitrotoluene affects the expression of SNX25 mRNA | CTD | PMID:21346803 | 4,4'-sulfonyldiphenol | multiple interactions | ISO | SNX25 (Homo sapiens) | 6480464 | [bisphenol S co-treated with Fulvestrant] results in decreased methylation of SNX25 gene | CTD | PMID:31601247 | acrylamide | increases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Acrylamide results in increased expression of SNX25 mRNA | CTD | PMID:32763439 | Aflatoxin B2 alpha | decreases methylation | ISO | SNX25 (Homo sapiens) | 6480464 | aflatoxin B2 results in decreased methylation of SNX25 intron | CTD | PMID:30157460 | aristolochic acid A | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | aristolochic acid I results in decreased expression of SNX25 mRNA | CTD | PMID:33212167 | benzo[a]pyrene | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased expression of SNX25 mRNA | CTD | PMID:20064835 | benzo[a]pyrene | affects methylation | ISO | SNX25 (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the methylation of SNX25 promoter | CTD | PMID:27901495 | benzo[a]pyrene | increases expression | ISO | Snx25 (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of SNX25 mRNA | CTD | PMID:22228805 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | 7 more ... | CTD | PMID:19150397 | benzo[e]pyrene | decreases methylation | ISO | SNX25 (Homo sapiens) | 6480464 | benzo(e)pyrene results in decreased methylation of SNX25 intron | CTD | PMID:30157460 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of SNX25 mRNA | CTD | PMID:25181051 and PMID:30816183 | bisphenol A | increases expression | ISO | Snx25 (Mus musculus) | 6480464 | bisphenol A results in increased expression of SNX25 mRNA | CTD | PMID:33221593 | cadmium atom | increases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Cadmium results in increased expression of SNX25 mRNA | CTD | PMID:23369406 | cadmium dichloride | decreases expression | EXP | | 6480464 | Cadmium Chloride results in decreased expression of SNX25 mRNA | CTD | PMID:33453195 | calcitriol | multiple interactions | ISO | SNX25 (Homo sapiens) | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of SNX25 mRNA | CTD | PMID:21592394 | calcitriol | increases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Calcitriol results in increased expression of SNX25 mRNA | CTD | PMID:21592394 | carbon nanotube | decreases expression | ISO | Snx25 (Mus musculus) | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | CGP 52608 | multiple interactions | ISO | SNX25 (Homo sapiens) | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to SNX25 gene] | CTD | PMID:28238834 | chromium(6+) | affects expression | ISO | Snx25 (Mus musculus) | 6480464 | chromium hexavalent ion affects the expression of SNX25 mRNA | CTD | PMID:28472532 | copper(II) sulfate | increases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Copper Sulfate results in increased expression of SNX25 mRNA | CTD | PMID:19549813 | coumestrol | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Coumestrol results in decreased expression of SNX25 mRNA | CTD | PMID:19167446 | dicrotophos | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | dicrotophos results in decreased expression of SNX25 mRNA | CTD | PMID:28302478 | dorsomorphin | multiple interactions | ISO | SNX25 (Homo sapiens) | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Doxorubicin results in decreased expression of SNX25 mRNA | CTD | PMID:29803840 | epoxiconazole | decreases expression | ISO | Snx25 (Mus musculus) | 6480464 | epoxiconazole results in decreased expression of SNX25 mRNA | CTD | PMID:35436446 | ethyl methanesulfonate | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Ethyl Methanesulfonate results in decreased expression of SNX25 mRNA | CTD | PMID:23649840 | flutamide | decreases expression | EXP | | 6480464 | Flutamide results in decreased expression of SNX25 mRNA | CTD | PMID:24793618 | folic acid | multiple interactions | ISO | Snx25 (Mus musculus) | 6480464 | [1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of SNX25 mRNA | CTD | PMID:22206623 | formaldehyde | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Formaldehyde results in decreased expression of SNX25 mRNA | CTD | PMID:23649840 | FR900359 | affects phosphorylation | ISO | SNX25 (Homo sapiens) | 6480464 | FR900359 affects the phosphorylation of SNX25 protein | CTD | PMID:37730182 | fulvestrant | multiple interactions | ISO | SNX25 (Homo sapiens) | 6480464 | [bisphenol S co-treated with Fulvestrant] results in decreased methylation of SNX25 gene | CTD | PMID:31601247 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of SNX25 mRNA | CTD | PMID:22061828 | hydrogen peroxide | affects expression | ISO | SNX25 (Homo sapiens) | 6480464 | Hydrogen Peroxide affects the expression of SNX25 mRNA | CTD | PMID:20044591 | inulin | multiple interactions | ISO | Snx25 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of SNX25 mRNA | CTD | PMID:36331819 | methapyrilene | decreases methylation | ISO | SNX25 (Homo sapiens) | 6480464 | Methapyrilene results in decreased methylation of SNX25 intron | CTD | PMID:30157460 | methotrexate | increases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Methotrexate results in increased expression of SNX25 mRNA | CTD | PMID:24449571 | methyl methanesulfonate | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Methyl Methanesulfonate results in decreased expression of SNX25 mRNA | CTD | PMID:23649840 | methylmercury chloride | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | methylmercuric chloride results in decreased expression of SNX25 mRNA | CTD | PMID:28001369 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of SNX25 mRNA | CTD | PMID:25729387 | panobinostat | multiple interactions | ISO | SNX25 (Homo sapiens) | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA | CTD | PMID:27188386 | panobinostat | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | panobinostat results in decreased expression of SNX25 mRNA | CTD | PMID:26272509 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of SNX25 mRNA | CTD | PMID:33387578 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Snx25 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of SNX25 mRNA | CTD | PMID:36331819 | potassium chromate | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | potassium chromate(VI) results in decreased expression of SNX25 mRNA | CTD | PMID:22079256 | potassium chromate | multiple interactions | ISO | SNX25 (Homo sapiens) | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SNX25 mRNA | CTD | PMID:22079256 | SB 431542 | multiple interactions | ISO | SNX25 (Homo sapiens) | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | sulforaphane | decreases expression | ISO | Snx25 (Mus musculus) | 6480464 | sulforaphane results in decreased expression of SNX25 mRNA | CTD | PMID:30529165 | sulindac | increases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Sulindac results in increased expression of SNX25 mRNA | CTD | PMID:11906190 | sunitinib | increases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Sunitinib results in increased expression of SNX25 mRNA | CTD | PMID:31533062 | testosterone | multiple interactions | ISO | SNX25 (Homo sapiens) | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of SNX25 mRNA | CTD | PMID:21592394 | testosterone | increases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Testosterone results in increased expression of SNX25 mRNA | CTD | PMID:21592394 | tetrachloromethane | decreases expression | EXP | | 6480464 | Carbon Tetrachloride results in decreased expression of SNX25 mRNA | CTD | PMID:31150632 | thioacetamide | decreases expression | EXP | | 6480464 | Thioacetamide results in decreased expression of SNX25 mRNA | CTD | PMID:34492290 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of SNX25 mRNA | CTD | PMID:25729387 | trichostatin A | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of SNX25 mRNA | CTD | PMID:24935251 and PMID:26272509 | trichostatin A | affects expression | ISO | SNX25 (Homo sapiens) | 6480464 | trichostatin A affects the expression of SNX25 mRNA | CTD | PMID:28542535 | trichostatin A | multiple interactions | ISO | SNX25 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA | CTD | PMID:27188386 | trovafloxacin | decreases expression | ISO | Snx25 (Mus musculus) | 6480464 | trovafloxacin results in decreased expression of SNX25 mRNA | CTD | PMID:35537566 | urethane | increases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Urethane results in increased expression of SNX25 mRNA | CTD | PMID:28818685 | valproic acid | increases methylation | ISO | SNX25 (Homo sapiens) | 6480464 | Valproic Acid results in increased methylation of SNX25 gene | CTD | PMID:29154799 | valproic acid | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of SNX25 mRNA | CTD | PMID:23179753 more ... | valproic acid | multiple interactions | ISO | SNX25 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA | CTD | PMID:27188386 | vincristine | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | Vincristine results in decreased expression of SNX25 mRNA | CTD | PMID:23649840 | vorinostat | multiple interactions | ISO | SNX25 (Homo sapiens) | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNX25 mRNA | CTD | PMID:27188386 | vorinostat | decreases expression | ISO | SNX25 (Homo sapiens) | 6480464 | vorinostat results in decreased expression of SNX25 mRNA | CTD | PMID:26272509 | |